Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MLYS
stocks logo

MLYS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.440
-55.1%
--
--
-0.533
-32.49%
--
--
-0.547
-17.17%
Estimates Revision
Stock Price
Go Up
up Image
+11.81%
In Past 3 Month
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 47.29 USD with a low forecast of 26.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 47.29 USD with a low forecast of 26.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 38.910
sliders
Low
26.00
Averages
47.29
High
56.00
Current: 38.910
sliders
Low
26.00
Averages
47.29
High
56.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$52 -> $56
2025-11-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$52 -> $56
2025-11-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Mineralys Therapeutics to $56 from $52 and keeps a Buy rating on the shares. The firm is "enthusiastic" as Mineralys heads towards the near-term application submission for its oral selective aldosterone synthase inhibitor candidate lorundrostat.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$42 -> $52
2025-10-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$42 -> $52
2025-10-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Mineralys Therapeutics to $52 from $42 and keeps a Buy rating on the shares. The firm says its key onion leader conversations on the unmet need for resistant and uncontrolled hypertension patients is "supportive" of lorundrostat's profile in uncontrolled and resistant hypertension.
Wells Fargo
Overweight
upgrade
$26 -> $50
2025-09-11
Reason
Wells Fargo
Price Target
$26 -> $50
2025-09-11
upgrade
Overweight
Reason
Wells Fargo raised the firm's price target on Mineralys Therapeutics to $50 from $26 and keeps an Overweight rating on the shares, reflecting increased probability in hypertension and confidence in competitive positioning. The firm sees the investment thesis revolving more around the M&A case over the next few quarters.
Jefferies
Hold
initiated
$15
2025-06-10
Reason
Jefferies
Price Target
$15
2025-06-10
initiated
Hold
Reason
Guggenheim
Seamus Fernandez
Buy
downgrade
$52 -> $48
2025-05-14
Reason
Guggenheim
Seamus Fernandez
Price Target
$52 -> $48
2025-05-14
downgrade
Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Maintains
$30 → $42
2025-04-02
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30 → $42
2025-04-02
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mineralys Therapeutics Inc (MLYS.O) is -19.21, compared to its 5-year average forward P/E of -5.56. For a more detailed relative valuation and DCF analysis to assess Mineralys Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.56
Current PE
-19.21
Overvalued PE
-0.95
Undervalued PE
-10.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.66
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.33
Undervalued EV/EBITDA
-7.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 3794.73% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 516.79% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 3794.73% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MLYS News & Events

Events Timeline

(ET)
2025-11-14
12:01:56
Mineralys Therapeutics Experiences a 11.3% Decline
select
2025-11-14
10:01:43
Mineralys Therapeutics Experiences a 13.9% Decline
select
2025-11-10 (ET)
2025-11-10
16:33:17
Mineralys Therapeutics Announces Q3 EPS of 52 Cents, Below Consensus Estimate of 61 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-04NASDAQ.COM
Significant Wednesday Options Trading: CPRI, AXP, MLYS

  • American Express Options Trading: American Express Co. (AXP) experienced a significant options trading volume of 14,568 contracts, with a notable focus on the $345 strike put option expiring on December 5, 2025, which saw 2,599 contracts traded.

  • Mineralys Therapeutics Options Trading: Mineralys Therapeutics Inc. (MLYS) also had a high options trading volume of 10,519 contracts, particularly for the $30 strike put option expiring on March 20, 2026, with 3,500 contracts traded.

  • Trading Volume Comparison: The options trading volumes for both AXP and MLYS represented approximately 57.5% and 56.2% of their respective average daily trading volumes over the past month.

  • Further Information: For additional details on available expirations for CPRI, AXP, or MLYS options, StockOptionsChannel.com can be visited.

[object Object]
Preview
4.0
11-12Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Mineralys Therapeutics and Increases Price Target to $56

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and information.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
4.0
11-12NASDAQ.COM
Wells Fargo Continues Overweight Rating for Mineralys Therapeutics (MLYS)

  • Wells Fargo Coverage: On November 11, 2025, Wells Fargo maintained an Overweight recommendation for Mineralys Therapeutics (NasdaqGS:MLYS), despite a projected average price target of $44.62/share indicating a 5.42% downside from its recent closing price of $47.18/share.

  • Fund Sentiment: There are 327 funds reporting positions in Mineralys Therapeutics, reflecting a 5.14% increase in ownership over the last quarter, with total shares owned by institutions rising by 13.73% to 73,091K shares.

  • Ownership Breakdown: Major shareholders include Catalys Pacific (11.48% ownership), Ra Capital Management (7.92%), and Samsara BioCapital (7.32%), with no changes in their holdings over the last quarter.

  • Market Outlook: The put/call ratio for MLYS stands at 2.98, suggesting a bearish outlook among investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mineralys Therapeutics Inc (MLYS) stock price today?

The current price of MLYS is 38.91 USD — it has decreased -0.74 % in the last trading day.

arrow icon

What is Mineralys Therapeutics Inc (MLYS)'s business?

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.

arrow icon

What is the price predicton of MLYS Stock?

Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 47.29 USD with a low forecast of 26.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mineralys Therapeutics Inc (MLYS)'s revenue for the last quarter?

Mineralys Therapeutics Inc revenue for the last quarter amounts to -41.13M USD, decreased -31.57 % YoY.

arrow icon

What is Mineralys Therapeutics Inc (MLYS)'s earnings per share (EPS) for the last quarter?

Mineralys Therapeutics Inc. EPS for the last quarter amounts to -28872000.00 USD, decreased -42.51 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mineralys Therapeutics Inc (MLYS)'s fundamentals?

The market is revising No Change the revenue expectations for MLYS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 11.81%.
arrow icon

How many employees does Mineralys Therapeutics Inc (MLYS). have?

Mineralys Therapeutics Inc (MLYS) has 51 emplpoyees as of December 05 2025.

arrow icon

What is Mineralys Therapeutics Inc (MLYS) market cap?

Today MLYS has the market capitalization of 3.08B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free